The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...
Data reported today include safety, biopsy and arrhythmia results from three patients who received TN-401 at a dose of 3E13 vg/kg. Patient follow-up at the time of data cut off ranged from 20-40 weeks ...
Before her death earlier this month, Madeleine Sophie Wickham, known by her pen name Sophie Kinsella, was known for creating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback